Get E-Book on COVID-19

Immune Disorders Data Verified

Role of Biologics (Omalizumab) in Chronic Urticaria

Written by
Dr. Suvash Sahu
and medically reviewed by iCliniq medical review team.

Published on Nov 15, 2016 and last reviewed on Sep 07, 2018   -  2 min read



Omalizumab is a newer therapy for patients with chronic urticaria. In this article, I have discussed in detail about the mechanism of action, use, dosage, side effects and precautions of Omalizumab.

Role of Biologics (Omalizumab) in Chronic Urticaria

Omalizumab, an antibody derived from murine blood acts against human immunoglobulin E (IgE). This drug was approved by FDA (Food and Drug Administration) for use in chronic idiopathic urticaria. It can be used in a patient who does not respond to approved doses of H1 antihistamines.

Mechanism of Action:

Basophils and mast cells are store house of various allergy causing mediators. These mediators are released when IgE in the body binds to receptors present over these cells. Omalizumab inhibits this phenomenon of binding IgE to these cells. Omalizumab binds to free IgE in the body fluids with much higher affinity, thus preventing binding of IgE to the receptors present over basophils and mast cells.

Omalizumab does not bind to already receptor bound IgE or to the receptor directly. These binding characteristics allow Omalizumab to neutralize IgE mediated responses without release of allergy causing mediators.

Usage and Dose of Omalizumab:

  1. In chronic idiopathic urticaria, subcutaneous injection of 150 to 300 mg repeated every two to four weeks for 12 weeks.
  2. In case of atopic dermatitis, systemic mastocytosis and bullous urticaria, 150 to 300 mg subcutaneous injection two to four weekly.

Side Effects:

Special Consideration Before Administration:

This drug should be administered by a physician or a healthcare professional, who is trained in recognition and treatment of anaphylaxis. Symptoms of systemic eosinophilia along with clinical features of urticarial vasculitis occurs more often in patients who are on Omalizumab, which usually reduce with oral corticosteroid dosage.

Some patients have experienced some signs and symptoms, including joint pain, skin rashes, fever and enlargement of lymph node in the form of painful pea shaped swelling in the axilla or groin areas. This usually occurs with an onset of one to five days after the first and subsequent injections of Omalizumab. Therapy should be discontinued if such symptoms occur.

For further information about Omalizumab consult a dermatologist online -->


This is a sponsored Ad. icliniq or icliniq doctors do not endorse the content in the Ad.

Last reviewed at:
07 Sep 2018  -  2 min read


Dr. Suvash Sahu

Dr. Suvash Sahu


Consult by PhoneConsult by Phone Video ChatVideo Chat


Comprehensive Medical Second Opinion.Submit your Case

Related Questions & Answers

Please suggest homeopathy medicine for urticaria.

Query: Hi doctor, I am a 30 year old male. Recently, I have been diagnosed with having urticaria (burning, itching sensations throughout the body from head to toe). It started out in an acute way but is turning out to be chronic. It has been more than two and a half months and I am still suffering from it...  Read Full »

My wife has urticaria. Please help.

Query: Hello doctor, My wife has been getting a rash which the doctor has termed as urticaria. What could have caused this? I feel she could be having a yeast intolerance. Please help.  Read Full »

Popular Articles Most Popular Articles

Do you have a question on ?

Ask a Doctor Online

* guaranteed answer within 4 hours.

Disclaimer: All health articles published on this website is not intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek the advice from your physician or other qualified health-care providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website.